# BridgeBio Pharma\, Inc\. (BBIO), Q3 FY2026

League: [Public league\, quarters ending July to September 2026](/leagues/2026q3.md). Company: [/companies/bbio](/companies/bbio.md).

| Field | Value |
| --- | --- |
| Fiscal period | Q3 FY2026 |
| Period end | 2026-09-30 |
| Report due by | 2026-11-06 |
| Margin metric | Operating margin |
| Status | Scored |

Locked Oct 29, 2026, 16:03 ET by the 8-K (2.02 Results of operations), accession 0001743881-26-000033.

## Reported

As first reported in accession 0001743881-26-000034, scored Oct 29, 2026.

| Metric | Actual | Tolerance |
| --- | --- | --- |
| Revenue | $353.2m | 10% of the actual: $35.3m |
| Diluted EPS | −$0.42 | 20% of the actual, at least $0.05: $0.08 |
| Operating margin | −3.3% | 5 percentage points |

Formula: `score = 100 × max(0, 1 − |forecast − actual| / tolerance)`

## Forecasts

Members with a public profile. 0 more forecast privately.

No public forecasts.